Tormere Analytics
OverviewStock ResearchChartsPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Articles
Pricing
Privacy PolicyTerms of Service

RCKT

$2.56-1.16%website ↗⬇ financials (.py)

ROCKET PHARMACEUTICALS, INC.

Market Cap
$280M
Live price × shares (2026-09-17)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
0.49
60mo monthly vs SPY
P/E (TTM)
N/M
Price / TTM net income
P/S (TTM)
—
Price / TTM revenue
P/B
0.8
Price / stockholders equity
EV/EBITDA
—
TTM
Price Chart
Loading…

Signals

Insider Velocity
9.9x
selling
Congress
—
recent trades
Short Volume
54%
W/W -2.7pp

Market & Alt Data

News
15
recent articles
Activist
13D
ROCKET
Analyst Consensus
Buy
20 analysts
Velocity Score
9.90x
Sell Rate (90d)
1399.74/mo
Sell Baseline
372.98/mo
Unique Sellers (90d)
4
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-09-112026-09-15Wilson MartinGeneral CounselSale75.4K$3.40$256K598.5KView
2026-08-182026-08-20Shah GauravCEOSale2,293$3.38$8K1.06MView
2026-08-182026-08-20Wilson MartinGeneral CounselSale631$3.38$2K673.9KView
2026-08-132026-08-17Wilson MartinGeneral CounselSale3,493$3.38$12K674.5KView
2026-08-132026-08-17Shah GauravCEOSale2,837$3.38$10K1.06MView
1–5 of 28
1 / 6

Reporting Insiders

  • Martin Wilson
    General Counsel
    3 transactions · last 2026-09-11
  • Gaurav Shah
    CEO
    2 transactions · last 2026-08-18
  • Sarbani Chaudhuri
    See Remarks
    1 transaction · last 2026-08-11
  • Christopher James Stevens
    Chief Operating Officer
    1 transaction · last 2026-08-11
  • Gaurav Shah
    CEO
    5 transactions · last 2026-05-21
  • John Militello
    See Remarks
    14 transactions · last 2026-05-19
  • Martin Wilson
    General Counsel
    4 transactions · last 2026-05-19

Gov Contracts

AgencyAmountAwarded
National Aeronautics and Space Administration$3.4B2015-11-01
Department of Defense$1.1B2013-10-31

Recent News

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
Yahoo · 2026-09-22
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Yahoo · 2026-09-18
This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Benzinga · 2026-09-17
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Yahoo · 2026-09-16
Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls
Yahoo · 2026-09-16
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Airbnb, Booking Holdings, Credicorp, Dutch Bros, Expedia, Hartford Financial Services, Group, Meritage Homes, Patchex, Yum! Brands, and More
Yahoo · 2026-09-16
Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock
Yahoo · 2026-09-16
This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Benzinga · 2026-09-16
Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target
Benzinga · 2026-09-16
Rocket Pharma stock upgraded at Needham (RCKT:NASDAQ)
Seeking Alpha · 2026-09-16
Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target
Benzinga · 2026-09-16
Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial
Yahoo · 2026-09-15
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights
Yahoo · 2026-09-15
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Yahoo Finance · 2026-09-15
Former Rocket Pharma (NASDAQ: RCKT) exec plans stock sale
Stock Titan · 2026-09-11

Informational purposes only, not investment advice.

ROCKET PHARMACEUTICALS, INC. (RCKT)

tormere.com/research/RCKT · generated 2026-10-04

$2.56
-1.16%
General Information
Price$2.56
Change-1.16%
Market Cap$280M
SectorHealth Care
IndustryBiotechnology
ExchangeNasdaq
Beta (raw, 60mo vs SPY)0.49
Signals
Insider Velocity9.9x selling
Congress Trades—
  • Sarbani Chaudhuri
    See Remarks
    1 transaction · last 2026-05-07
  • Short Volume
    54% of daily vol
    Conviction Score15/100
    Analyst ConsensusSB 4 · B 7 · H 7 · S 2 · SS 0
    Price Chart (1 Year)
    2025-10-062026-10-02$5.30$2.56
    Recent Insider Activity (Form 4) — Last 5
    DateInsiderTypeSharesValue
    2026-09-11Wilson MartinS75,364$256,463.69
    2026-08-18Shah GauravS2,293$7,752.63
    2026-08-18Wilson MartinS631$2,133.41
    2026-08-13Wilson MartinS3,493$11,809.83
    2026-08-13Shah GauravS2,837$9,591.9
    Recent News
    • Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? — Yahoo · 2026-09-22
    • Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug — Yahoo · 2026-09-18
    • This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday — Benzinga · 2026-09-17
    • RCKT Aligns With FDA on Completing Phase II Study in Danon Disease — Yahoo · 2026-09-16
    • Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls — Yahoo · 2026-09-16

    Tormere — informational purposes only, not investment advice.

    Factor Profile

    Pro
    Pro feature

    Fama-French factor analysis is available on the Pro plan.

    Upgrade to Pro →